More than 1 in 8 participants treated with retatrutide became completely free of knee pain by the end of the trial
Evolve Peptides provides products strictly for research purposes only
The FDA typically allowed 60 days for 503A pharmacies and 90 days for 503B facilities to wind down their operations
[Study presented at scientific congresses] Kelly AS, et al
Retatrutide is an investigational triple-receptor agonist developed by Eli Lilly
Method 1: The detailed steps for synthesizing Retarutide using solid-state synthesis in the laboratory are as follows: Prepare the required reagents and instruments: including amino acids, dichloromethane, potassium carbonate, ethoxylated silica gel, acetonitrile, pyridine, N-methylmorpholine, diisopropylethyl chloride source, trifluoroacetic acid, DIPEA, Boc protected amino acids and other reagents, as well as magnetic stirrers, rotary evaporators and other instruments